4.5 Editorial Material

Inhibiting citrullination in rheumatoid arthritis: taking fuel from the fire

Journal

ARTHRITIS RESEARCH & THERAPY
Volume 14, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/ar3740

Keywords

-

Categories

Funding

  1. National Institute for Health Research [CL-2008-21-015] Funding Source: researchfish

Ask authors/readers for more resources

Citrullination is a post-translational modification catalysed by peptidylarginine deiminase and is a common feature of inflammation. The presence of anti-citrullinated protein/peptide antibodies (ACPA), however, is unique to rheumatoid arthritis. Several lines of evidence suggest that ACPA are important in the pathogenesis of rheumatoid arthritis. A popular hypothesis for this pathogenesis is a two-hit model. The first hit gives rise to ACPA, and the second hit, an unrelated episode of synovial inflammation accompanied by citrullination, is perpetuated by the pre-existing antibodies. This model suggests that reducing citrullination might ameliorate disease. Recent findings indicate that citrullination closely correlates with inflammation, and that glucocorticoids decrease peptidylarginine deiminase expression independent of their other anti-inflammatory effects.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Rheumatology

Health-related quality of life and costs in Sjogren's syndrome

Samira T. Miyamoto, Valeria Valim, Benjamin A. Fisher

Summary: HRQoL in SS patients is significantly reduced, similar to other chronic diseases, with no proven therapy to improve it. Although SS generally does not affect life expectancy, the associated costs and work disability are still concerning.

RHEUMATOLOGY (2021)

Article Rheumatology

Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjogren's Syndrome: A Randomized Clinical Trial

James Posada, Saba Valadkhan, Daniel Burge, Kristen Davies, Jessica Tarn, John Casement, Kerry Jobling, Peter Gallagher, Douglas Wilson, Francesca Barone, Benjamin A. Fisher, Wan-Fai Ng

Summary: In patients with primary SS, treatment with RSLV-132 led to clinically significant improvements in ESSPRI score, FACIT-F score, ProF score, and DSST, while placebo showed no changes in these measures. These improvements were correlated with increased expression of selected interferon-inducible genes.

ARTHRITIS & RHEUMATOLOGY (2021)

Article Rheumatology

The management of Sjogren's syndrome: British Society for Rheumatology guideline scope

Elizabeth Price, Alexander Allen, Saaeha Rauz, Anwar Tappuni, Nurhan Sutcliffe, Michele Bombardieri, Sara Carty, Coziana Ciurtin, Bridget Crampton, Lisa Duncalfe, Benjamin Fisher, Peter Glennon, Katie L. Hackett, Genevieve Larkin, Wan-Fai Ng, Athimalaipet Ramanan, Saad Rassam, Stephen B. Walsh, Simon Bowman

Summary: The guideline will be developed following the methods and processes outlined in Creating Clinical Guidelines: Our Protocol, and it has received accreditation from the National Institute for Health and Care Excellence (NICE) for producing guidance, advice, and recommendations for practice.

RHEUMATOLOGY (2021)

Letter Rheumatology

Comment on: Equal rights in autoimmunity: is Sjogren's syndrome ever 'secondary'?: reply

Florian Kollert, Benjamin A. Fisher

RHEUMATOLOGY (2021)

Article Geriatrics & Gerontology

Therapeutic Recommendations for the Management of Older Adult Patients with Sjogren's Syndrome

Soledad Retamozo, Chiara Baldini, Hendrika Bootsma, Salvatore De Vita, Thomas Doerner, Benjamin A. Fisher, Jacques-Eric Gottenberg, Gabriela Hernandez-Molina, Agnes Kocher, Belchin Kostov, Aike A. Kruize, Thomas Mandl, Wan-Fai Ng, Raphaele Seror, Yehuda Shoenfeld, Antoni Siso-Almirall, Athanasios G. Tzioufas, Arjan Vissink, Claudio Vitali, Simon J. Bowman, Xavier Mariette, Manuel Ramos-Casals, Pilar Brito-Zeron

Summary: Primary Sjogren's syndrome is a systemic autoimmune disease commonly diagnosed in middle-aged women, with two-thirds of patients diagnosed between 30 and 60 years old. Older patients are more likely to have organ-related comorbidities and require caution when using various medications. A thorough evaluation of medical history is essential for older patients when prescribing drugs included in the EULAR guidelines, with specific attention to factors commonly associated with aging.

DRUGS & AGING (2021)

Letter Rheumatology

Cytokines and Fatigue in Sjogrens Syndrome: An Evolving Landscape Reply

James Posada, Benjamin A. Fisher, Wan-Fai Ng

ARTHRITIS & RHEUMATOLOGY (2021)

Meeting Abstract Rheumatology

IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL

T. Dorner, S. J. Bowman, R. Fox, X. Mariette, A. Papas, T. Grader-Beck, B. A. Fisher, F. Barcelos, S. De Vita, H. Schulze-Koops, R. J. Moots, G. Junge, J. Woznicki, M. Sopala, W. L. Luo, W. Hueber

ANNALS OF THE RHEUMATIC DISEASES (2021)

Article Critical Care Medicine

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST) : a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Benjamin A. Fisher, Tonny Veenith, Daniel Slade, Charlotte Gaskell, Matthew Rowland, Tony Whitehouse, James Scriven, Dhruv Parekh, Madhu S. Balasubramaniam, Graham Cooke, Nick Morley, Zoe Gabriel, Matthew P. Wise, Joanna Porter, Helen McShane, Ling-Pei Ho, Philip N. Newsome, Anna Rowe, Rowena Sharpe, David R. Thickett, Julian Bion, Simon Gates, Duncan Richards, Pamela Kearns

Summary: This study aimed to evaluate the efficacy of two drugs in hospitalized patients with COVID-19. The results showed that namilumab was able to reduce the inflammatory response, while infliximab did not show significant efficacy compared to usual care. Although there were some differences in adverse events and mortality rates, these differences were not significant.

LANCET RESPIRATORY MEDICINE (2022)

Letter Rheumatology

History of tonsillectomy is associated with glandular inflammation in Sjogren's disease

Florian Kollert, Valentina Pucino, Saba Nayar, Jason Turner, Saaeha Rauz, Andrea Richards, Jon Higham, Ana Poveda-Gallego, Rachel M. Brown, Timothy Bates, Simon J. Bowman, Francesca Barone, Benjamin A. Fisher

RHEUMATOLOGY (2022)

Article Rheumatology

Sjogren's and non-Sjogren's sicca share a similar symptom burden but with a distinct symptom-associated proteomic signature

Valentina Pucino, Jason D. Turner, Saba Nayar, Florian Kollert, Saaeha Rauz, Andrea Richards, Jon Higham, Ana Poveda-Gallego, Simon J. Bowman, Francesca Barone, Benjamin A. Fisher

Summary: This study aimed to compare clinical and proteomic predictors of primary Sjogren's syndrome (SjS) and non-SjS sicca syndrome (sicca), and identify the key predictors of symptoms. The results showed that obesity-related metabolic factors may regulate symptoms in sicca, while further research is needed to explore the non-inflammatory drivers of high symptom burden in SjS.

RMD OPEN (2022)

Meeting Abstract Rheumatology

Comparative Treatment Effectiveness in Rheumatoid Arthritis with and Without Concomitant Sjogren's Syndrome - Results from the Swiss Clinical Quality Management Cohort

Lisa Christ, Seraphina Kissling, Ruediger B. Mueller, Axel Finckh, Benjamin Fisher, Britta Maurer, Burkhard Moeller, Florian Kollert

ARTHRITIS & RHEUMATOLOGY (2021)

Meeting Abstract Rheumatology

Potential Predictors of Persistence in Immune Check Point Inhibitor Induced Arthritis

Anu Desai, Lakshmi Priya Shadananan, Adam Croft, Lalit Pallan, Neil Steven, Benjamin Fisher

ARTHRITIS & RHEUMATOLOGY (2021)

Meeting Abstract Rheumatology

Ianalumab (VAY736) Safety and Efficacy in Patients with Sjogren's Syndrome: 52 Week Results from a Randomized, Placebo-controlled, Phase 2b Dose-ranging Trial

Thomas Doerner, Simon J. Bowman, Robert Fox, Xavier Mariette, Athena Papas, Thomas Grader-Beck, Ben A. Fisher, Filipe Barcelos, Salvatore De Vita, Hendrik Schulze-Koops, Robert Moots, Guido Junge, Janice Woznicki, Monika Sopala, Wen-Lin Luo, Wolfgang Hueber

ARTHRITIS & RHEUMATOLOGY (2021)

Article Medicine, General & Internal

CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults

Tonny Veenith, Benjamin A. Fisher, Daniel Slade, Anna Rowe, Rowena Sharpe, David R. Thickett, Tony Whitehouse, Matthew Rowland, James Scriven, Dhruv Parekh, Sarah J. Bowden, Joshua S. Savage, Duncan Richards, Julian Bion, Pamela Kearns, Simon Gates

Summary: The CATALYST trial aims to identify novel treatments for COVID-19 patients through immunomodulation to improve outcomes. The trial has been approved by the appropriate ethics committee and will disseminate results through national and international presentations and peer-reviewed publications.

BMJ OPEN (2021)

Meeting Abstract Rheumatology

A FIRST IN DISEASE PHASE 2A TRIAL OF GRANULOCYTE MONOCYTE COLONY STIMULATING FACTOR NEUTRALISATION FOR AXIAL SPONDYLOARTHRITIS (NAMASTE STUDY)

M. H. Al-Mossawi, C. Worth, J. McDonald, P. M. Machado, B. Fisher, A. Chan, K. Gaffney, N. Gullick, J. Packham, R. Sengupta, T. Corn, J. Teh, P. C. Taylor, P. Bowness

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY (2021)

No Data Available